JEMPERLI (dostarlimab-gxly) | Official Patient Website
SponsoredFind Out If JEMPERLI May Be The Right Option For You & Visit The Patient Site Today. Learn More About How JEMPERLI Works & How You May Be Eligible For Financial Support.Co-Pay Assistance · View Patient Information · Official Patient Site
Types: Official Patient Site, Co-Pay Options, Reimbursement Options, Patient …Learn About JEMPERLI
Learn About A Treatment Option And See If It May Be Right For You.
JEMPERLI (dostarlimab-gxly) | View Indication Information
SponsoredHCPs - Discover If JEMPERLI Is Right For Your Appropriate Patients. View Important Information And Resources About JEMPERLI. Get Medication Guide.See Dosing & Safety Info · Access JEMPERLI Info
Types: Prescribing Info, Medication Guide, Sign Up For Updates, Safety InformationSee The Facts & Stats
Read More About JEMPERLI And How It May Help Your Appropriate Patients.
KEYTRUDA® (pembrolizumab) | Learn About a Treatment Option
SponsoredDiscover More About KEYTRUDA on the Official Patient Site. Have Questions About KEYTRUDA? Find Information and Resources Here.Product Information · Doctor Discussion Guide · Financial Assistance
Types: Prescribing Information, Medication Guide, Safety Information, Cost Information
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of...
Expanded Role for Immunotherapy to Treat Endometrial Cancer
Apr 12, 2023 · UPDATE: On July 31, 2023, the Food and Drug Administration (FDA) approved dostarlimab (Jemperli) in combination with chemotherapy to treat people with endometrial cancer. The drug is approved for use with chemotherapy for newly diagnosed endometrial cancer that has spread or cancer that has come back after earlier treatment.
dMMR and Endometrial Cancer | JEMPERLI (dostarlimab-gxly)
Patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer may benefit from an option like JEMPERLI (dostarlimab-gxly) + CP. See full Indication, Safety, & PI.
FDA Approves Immunotherapy for Endometrial Cancer with …
Apr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on...
JEMPERLI - EC Treatment Option for Certain Patients
JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer. Discover JEMPERLI, a treatment option. Find information about dosing, side effects, resources, and more.
Jemperli: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 7, 2024 · Jemperli (dostarlimab-gxly) is a cancer immunotherapy used to treat types of endometrial cancer and solid tumors. Includes Jemperli side effects, indications, and doses.
Jemperli vs Keytruda for endometrial cancer: What’s the …
Sep 4, 2023 · Both Jemperli (dostarlimab) and Keytruda (pembrolizumab) are prescribed as second-line treatments for advanced endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Only Jemperli can be used as a …
Treatment Guide for Dostarlimab-gxly (Jemperli) for Endometrial Cancer
Nov 4, 2024 · Dostarlimab, as a single agent, for dMMR recurrent or endometrial cancer: 500 mg every 3 weeks for 4 doses followed or 1,000 mg every 6 weeks via IV infusion.
FDA Expands Approval for Jemperli in Endometrial Cancer
Aug 2, 2024 · The US Food and Drug Administration (FDA) has approved dostarlimab (Jemperli) in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for all adults with...
GSK gets European Commission nod for expanded use of Jemperli …
Jan 21, 2025 · The label for Jemperli plus chemotherapy in the US was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme.
ENHERTU® (fam-trastuzumab | deruxtecan-nxki) - HCP Info
SponsoredVisit Site For Dosing, MOA, & Clinical Trial Info. View PI & Boxed Warnings For ENHERTU. Healthcare Professionals: Access Educational Resources About ENHERTU For Your Patients.Types: ENHERTU Treatment Info, Clinical Trial Data, MOA & Dosing InfoIMFINZI® (durvalumab) Data | Indication
SponsoredLearn About A Treatment Option From IMFINZI. Visit The Official Site To Learn More. Discover The Dosing Info & Clinical Trial Data On The IMFINZI Physician Site.Uterine Cancer Care | Women's Health Specialists
SponsoredAdvanced Women's Health Care for Patients With Uterine Cancer. Learn More. World-Renowned Women's Health Care, With Doctors from Columbia and Weill Cornell.Service catalog: Video Visits Offered, Many Insurances Accepted, Comprehensive CareJEMPERLI (dostarlimab-gxly) | Official Patient Website
SponsoredFind Out If JEMPERLI May Be The Right Option For You & Visit The Patient Site Today. Learn More About How JEMPERLI Works & How You May Be Eligible For Financial Support.Co-Pay Assistance · View Patient Information · Official Patient Site
Types: Official Patient Site, Co-Pay Options, Reimbursement Options, Patient …Learn About JEMPERLI
Learn About A Treatment Option And See If It May Be Right For You.
